International Journal of Molecular Medical Science, 2025, Vol.15, No.6, 274-286 http://medscipublisher.com/index.php/ijmms 285 Kherabi Y., Pedersen O., Lange C., Bénézit F., Chesov D., Codecasa L., Dudnyk A., Kiria N., Konstantynovska O., Marigot-Outtandy D., Panciu T., Poignon C., Sasi S., Schaub D., Solodovnikova V., Vasiliauskaitė L., Yeghiazaryan L., Günther G., Guglielmetti L., Aubry A., Vasiliu A., Mclaughlin A., Lange C., Poignon C., Cirillo D., Podlekareva D., Davidavičienė E., Fumagalli G., Troia G., Günther G., Motta I., Jonsson J., Robert J., Eimer J., Kuska L., Guglielmetti L., Skowroński M., Fitzgibbon M., Revest M., Veziris N., Pedersen O., Konstantynovska O., Opota O., Viiklepp P., Coriu R., Tunesi S., Sasi S., Skogmar S., Bjerrum S., Togonidze T., Lillebaek T., Pourcher V., Le V., and Kherabi Y., 2025, Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study, The Lancet Regional Health-Europe, 56: 101380. https://doi.org/10.1016/j.lanepe.2025.101380 Kumar B., Sharma D., Venkatesan K., and Bisht D., 2025, Proteomic analysis of drug-resistant mycobacterium tuberculosis clinical isolates under aminoglycoside drug pressure, Current Microbiology, 82(8): 361. https://doi.org/10.1007/s00284-025-04341-8. Li B., Wen F., and Wang Z., 2022, Correlation between polymorphism of vitamin D receptor TaqI and susceptibility to tuberculosis, Medicine, 101(16): e29127. https://doi.org/10.1097/md.0000000000029127 Li C., Liang S., Wang X., Lui S., and Wang C., 2025, Risk factors associated with morbidity and unfavorable treatment outcome in drug-resistant pulmonary tuberculosis: a case-control study, Precision Clinical Medicine, 8(2): pbaf008. https://doi.org/10.1093/pcmedi/pbaf008 Liang D., Song Z., Liang X., Qin H., Huang L., Ye J., Lan R., Luo D., Zhao Y., and Lin M., 2023, Whole genomic analysis revealed high genetic diversity and drug-resistant characteristics of mycobacterium tuberculosis in Guangxi China, Infection and Drug Resistance, 16: 5021-5031. https://doi.org/10.2147/idr.s410828 Liebenberg D., Gordhan B., and Kana B., 2022, Drug resistant tuberculosis: implications for transmission diagnosis and disease management, Frontiers in Cellular and Infection Microbiology, 12: 943545. https://doi.org/10.3389/fcimb.2022.943545 Liu C., Wu L., Lin C., Wu H., Liu K., and Lee S., 2024, Association of tuberculosis risk with genetic polymorphisms of the immune checkpoint genes PDCD1 CTLA-4 and TIM3, PLOS ONE, 19(5): e0303431. https://doi.org/10.1371/journal.pone.0303431. Liu Q., Yang D., Qiu B., Martinez L., Ji Y., Song H., Li Z., and Wang J., 2021, Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China, PLoS Neglected Tropical Diseases, 15(1): e0009068. https://doi.org/10.1371/journal.pntd.0009068 Lv H., Zhang X., Zhang X., Bai J., You S., Li X., Li S., Wang Y., Zhang W., and Xu Y., 2024, Global prevalence and burden of multidrug-resistant tuberculosis from 1990 to 2019, BMC Infectious Diseases, 24(1): 243. https://doi.org/10.1186/s12879-024-09079-5 Michalik M., Lorenc T., Marcinkowski K., Muras M., Mikszta N., Mikszta J., Kantor K., and Marcinkowska J., 2025, Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review, GMS Hygiene and Infection Control, 20: 33. https://doi.org/10.3205/dgkh000562 Miiro E., Olum R., and Baluku B., 2023, Clinical features resistance patterns and treatment outcomes of drug-resistant extra-pulmonary tuberculosis: a scoping review, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 33: 100390. https://doi.org/10.1016/j.jctube.2023.100390 Motta I., Boeree M., Chesov D., Dheda K., Günther G., Horsburgh C., Kherabi Y., Lange C., Lienhardt C., McIlleron H., Paton N., Stagg H., Thwaites G., Udwadia Z., Van Crevel R., Velásquez G., Wilkinson R., and Guglielmetti L., 2023, Recent advances in the treatment of tuberculosis, Clinical Microbiology and Infection, 30(9): 1107-1114. https://doi.org/10.1016/j.cmi.2023.07.013 Samad N., Wardak G., Batool F., Kenoosh H., Opara N., Anwar N., Doraghi K., and Bashir M., 2024, Drug resistance pattern prevalence and risk factors for resistance to second line anti-tuberculosis drugs in Balochistan Pakistan, Romanian Journal of Infectious Diseases, 27(3): 237. https://doi.org/10.37897/rjid.2024.3.12 Soedarsono S., Mertaniasih N., Kusmiati T., Permatasari A., Ilahi W., and Anggraeni A., 2023, Characteristics of previous tuberculosis treatment history in patients with treatment failure and the impact on acquired drug-resistant tuberculosis, Antibiotics, 12(3): 598. https://doi.org/10.3390/antibiotics12030598 Song Z., Liu C., He W., Pei S., Liu D., Cao X., Wang Y., He P., Zhao B., Ou X., Xia H., Wang S., and Zhao Y., 2023, Insight into the drug-resistant characteristics and genetic diversity of multidrug-resistant ,mycobacterium tuberculosis in China, Microbiology Spectrum, 11(5): e01324-23. https://doi.org/10.1128/spectrum.01324-23 Varshney K., Anaele B., Molaei M., Frasso R., and Maio V., 2021, Risk factors for poor outcomes among patients with extensively drug-resistant tuberculosis (XDR-TB): a scoping review, Infection and Drug Resistance, 14: 5429-5448. https://doi.org/10.2147/idr.s339972 Venkatesh K., Usharani B., Anbazhagi M., Rakesh G., and Muthuraj M., 2021, Risk factors and treatment outcome analysis associated with second-line drug-resistant tuberculosis, Journal of Respiration, 2(1): 1-12. https://doi.org/10.3390/jor2010001 Wang J., Wang M., Li Z., Wu X., Zhang X., Julius A., Zhong H., Huang X., Chen M., Tan H., and Yi H., 2021, Impact of PD-1 gene polymorphism and its interaction with tea drinking on susceptibility to tuberculosis, Epidemiology and Infection, 149: e29. https://doi.org/10.1017/s0950268821000042
RkJQdWJsaXNoZXIy MjQ4ODYzNA==